GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CFO Kevin Feeley sold 1,285 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $108,222.70. Following the transaction, the chief financial officer directly owned 41,476 shares of the company’s stock, valued at approximately $3,493,108.72. This represents a 3.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kevin Feeley also recently made the following trade(s):
- On Tuesday, June 16th, Kevin Feeley sold 3,729 shares of GeneDx stock. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33.
GeneDx Price Performance
NASDAQ:WGS traded up $1.06 during trading hours on Friday, hitting $85.02. The stock had a trading volume of 331,592 shares, compared to its average volume of 938,779. The company has a 50 day simple moving average of $74.31 and a two-hundred day simple moving average of $66.65. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.30 and a quick ratio of 3.06. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -23.36 and a beta of 1.99.
Analyst Upgrades and Downgrades
WGS has been the topic of a number of research analyst reports. Weiss Ratings upgraded GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded GeneDx from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 26th. Piper Sandler restated an “overweight” rating and issued a $63.00 price objective (up from $50.00) on shares of GeneDx in a research report on Tuesday, June 23rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $90.00 target price on shares of GeneDx in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.57.
View Our Latest Stock Analysis on GeneDx
Institutional Investors Weigh In On GeneDx
Several hedge funds have recently added to or reduced their stakes in WGS. Cerity Partners LLC increased its position in shares of GeneDx by 6.0% during the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after purchasing an additional 142 shares during the last quarter. Main Management ETF Advisors LLC lifted its position in GeneDx by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after buying an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after buying an additional 181 shares during the last quarter. Strs Ohio boosted its stake in GeneDx by 8.7% in the first quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after buying an additional 200 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in GeneDx in the fourth quarter worth approximately $27,000. Institutional investors own 61.72% of the company’s stock.
About GeneDx
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
- Five stocks we like better than GeneDx
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
